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Despite considerable improvement in the management of
heart failure (HF), unsustainable levels of morbidity and
mortality coupled with an increasing economic and social
burden have been observed over the previous three decades
[1]. A rational explanation of this is the fact that no single
pathophysiologic paradigm of HF has been clariﬁed, result-
ing in failure of our current models to completely explain
disease progression [2].
Classically, seven categories of biomarkers in HF have
been described, reﬂecting the diﬀerent pathophysiological
pathways involved in disease progression [3]. These
include myocardial stretch, myocyte injury, matrix remod-
elling, inﬂammation, neurohumoral activation, oxidative
stress, and indices of renal dysfunction [4]. Moreover,
growing evidence supports the key role of alternative path-
ophysiological pathways (e.g., the gastrointestinal system,
the anabolic/catabolic imbalance, and multiple hormonal
deﬁciency syndrome), with ever-increasing identiﬁcations
of novel biomarkers that demonstrate their importance in
HF [5–9].
In this context, a growing interest in multimarker
approaches to biomarker panels to assessmultiple pathophys-
iologic pathways has been realised, including the combined
use of proteins, lipids, metabolites, hormones, and genetic
markers [10].
Owing to these recent advances in biomarker research,
the aim of this special issue was to focus on the role of bio-
markers in HF and associated diseases.
Ischemic heart disease is to date the most frequent
cause of HF [2], with atherosclerosis the major pathophys-
iological mechanism. In this issue, L.-D. Mocan Hognogi
et al. reviewed the role of adipokines (in particular visfatin,
apelin, leptin, and resistin) as biomarkers of ischemic car-
diac disease and concluded that “there is no doubt that
inﬂammation is viewed as an important pathophysiological
step in the development of atherosclerosis.”
Importantly, the identiﬁcation of patients at high risk of
poor prognosis is one of the principal aims of current clini-
cal research [11]. With this regard, M. Alavi-Moghaddam
et al. conducted a pilot study involving 21 patients diagnosed
with acute myocardial infarction and demonstrated that
plasma levels of microRNA-208b, of which levels of
expression have been demonstrated to be increased in
the blood of patients with acute myocardial infarction,
were 2-fold higher in patients who died after 6 months
than in those which survived.
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Further, J. Banach et al. investigated plasma concentra-
tion of procalcitonin (PCT) in 130 patients with chronic
HF with reduced ejection fraction, assessing its prognostic
value during a 24-month follow-up period. Indeed, PCT
levels were signiﬁcantly higher in HF patients when com-
pared to a control group. Further, Kaplan-Meier survival
curves revealed that patients with PCT in the highest quar-
tile had a signiﬁcantly reduced probability of survival. This
is additional evidence supporting the role of inﬂammation
in HF [7].
Diabetic cardiomyopathy (DCM) is a common cardiac
dysfunction, aﬀecting approximately 12% of diabetic
patients, and is featured by ventricular diastolic and (or) sys-
tolic dysfunction. N. Li et al. provided a comprehensive and
novel illustration of gene expression proﬁles to identify dif-
ferentially expressed genes in myocardial tissue, which may
play critical roles in the occurrence and development in
patients with DCM. This is of great interest considering that
diabetes mellitus has been described in approximately
20-25% of HF patients [5, 12].
HF is a progressive condition in which myocardial dam-
age, caused by cardiovascular risk factors, leads to the devel-
opment of myocardial dysfunction. Thus, an ever-worsening
condition is present until the patient eventually develops
end-stage heart failure. Heart transplantation is the only sur-
vival option for end-stage patients [2]. Cardiac allograft vas-
culopathy (CAV) is the leading cause of cardiovascular
adverse events during follow-up of heart transplantation. S.
Mirabet et al. demonstrated that high-sensitivity cardiac tro-
ponin T, measured during a long-term follow-up, appears as
a helpful biomarker to identify patients at low risk of adverse
CV outcomes. On the other hand, the soluble form of AXL
(sAXL) and a biomarker of endothelial dysfunction was
not able to predict outcome.
In conclusion, this issue collected novel ﬁndings and
shed light upon the role of biomarkers in HF.
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